VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation
- 320 Downloads
Activating BRAF mutations are observed in malignant melanomas, pleomorphic xanthoastrocytomas, hairy cell leukemia, papillary thyroid carcinomas, colorectal cancer, ovarian cancer and ganglioglioma [1, 10, 11]. Generation of a monoclonal antibody specific for the BRAF V600E mutation (VE1) was published recently . This antibody has been successfully validated for melanomas , lung adenocarcinomas  and thyroid carcinomas . Although pituitary adenomas account for up to 10 % of all intracranial tumors , there is still a lack of data on VE1 immunostains in these tumors. In three studies in which BRAF in pituitary adenomas was examined by sequencing, a single V600E mutation was found in 145 cases [6, 7, 10].